NCT06045052View on ClinicalTrials.gov

Eltrombopag for Treatment of Fanconi Anemia

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

June 19, 2023

Study Completion Date

August 29, 2023

Conditions
Fanconi Anemia
Interventions
DRUG

Eltrombopag

Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.

Trial Locations (1)

28009

Hospital Infantil Universitario Niño Jesús (HIUNJ), Madrid

All Listed Sponsors
lead

Julian Sevilla

OTHER

NCT06045052 - Eltrombopag for Treatment of Fanconi Anemia | Biotech Hunter | Biotech Hunter